Prosecution Insights
Last updated: November 20, 2026
Application No. 18/701,581

TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS USING NANO POLYMERS OF HISTONE DEACETYLASE INHIBITORS

Non-Final OA §102§103§DOUBLEPATENT
Filed
Apr 15, 2024
Priority
Oct 15, 2021 — provisional 63/256,246 +1 more
Examiner
WORSHAM, JESSICA N
Art Unit
1615
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
University of Virginia Patent Foundation
OA Round
1 (Non-Final)
56%
Grant Probability
Moderate
1-2
OA Rounds
4m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 56% of resolved cases
56%
Career Allowance Rate
428 granted / 757 resolved
-3.5% vs TC avg
Strong +56% interview lift
Without
With
+56.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
45 currently pending
Career history
812
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
42.0%
+2.0% vs TC avg
§102
13.4%
-26.6% vs TC avg
§112
25.8%
-14.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 757 resolved cases

Office Action

§102 §103 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Detailed Action Information Disclosure Statement The information disclosure statements (IDS) submitted on 15 April 2024 and 3 August 2026 are acknowledged. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements have been considered by the examiner. See attached copy of PTO-1449. Response to Restriction 2. Applicants’ election without traverse of Group I (claims 1, 3, and 5-10) in the reply filed on 3 August 2026 is acknowledged. Status of Application 3. The instant application is a national stage entry of PCT/US22/46905 filed 17 October 2022. Claims 1, 6, 8, 10-12, 14, 16-17, 19-21, 23-24, and 30-48 are currently pending. Claims 2-5, 7, 9, 13, 15, 18, 22, and 25-29 are cancelled. Claims 11-12, 14, 16-17, 19-21, 23-24, and 42-48 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 3 August 2026. Claims 1, 6, 8, 10, and 30-41 are examined on the merits within. Claim Rejections – 35 U.S.C. 102 4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. 5. Claim(s) 1, 6, 8, 10, 30-35, 37 and 40-41 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Sirianni et al. (U.S. Patent Application Publication No. 2020/0054562). Regarding instant claim 1, Sirianni et al. disclose a nanoparticle comprising an amphiphilic polymer and a water insoluble biologically active ingredient. See claim 1. The active ingredient comprises a histone deacetylase inhibitor. See claim 41. Regarding instant claims 6 and 30, the polymer is a poly(lactic acid)-polyethylene glycol) (PLA-PEG) polymer or poly(lactic-co-glycolic acid)-poly(ethylene glycol). See claim 33. Regarding instant claim 8, non-limiting examples of the amphiphilic polymer include poly(lactic acid)-poly(ethylene glycol) (PLA-PEG), poly(lactic-co-glycolic acid)-poly(ethylene glycol) (PLGA-PEG), any salts of the foregoing, and any derivatives of the foregoing, etc. See paragraph [0057]. As used herein, the term “derivative” refers to a compound that is synthesized from a parent compound by replacement of one atom with another atom or group of atoms. Non-limiting examples of derivative include a salt, a pharmaceutically acceptable salt, and chemical modifications with a group including but not limited to esters, fluorine, methoxy, ethyl, butyl, propyl, hexyl, or other organic moieties. See paragraph [0039]. Regarding instant claim 10, 5 mg quisinostat was combined with 50 mg PLA-PEG (1:10). See paragraph [0147-0149]. Regarding instant claims 31-34, Sirianni et al. disclose use of Poly(d,l-lactide)-b-methoxy poly(ethylene glycol) (PLA-PEG, Mw˜16 k:5 k Da or PLA-PEG, Mw˜20 k:5 k). See paragraph [0144]. Regarding instant claim 35, the weight average molecular weight of PLA is between 5000 and 35000 daltons. See paragraph [0062]. The weight average molecular weight of PEG is between 1000 and 10000 daltons. See paragraph [0063]. The ratio of PLA and PEG (PLA:PEG) is between 50:5 and 10:5, or any number range in between, e.g., about 40:5, about 35:5, about 30:5, about 20:5 or about 16:5. See paragraph [0064]. Regarding instant claim 37, the composition comprises a surfactant. See paragraph [0014]. Examples include poloxamers. See paragraph [0073]. Regarding instant claims 40-41, active ingredients include vorinostat and romidepsin. See paragraph [0018]. Thus the instant claims are anticipated by Sirianni et al. 6. Claim(s) 1, 6, 10, 30-31, and 40 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Mohamed et al. (J. Pharm. Science, 2012). Regarding instant claims 1, 6, 10, 30-31, and 40, Mohamed et al. disclose poly(ethylene glycol)-b-poly(DL-lactic acid) micelles of Vorinostat. The micelles had nanoscopic mean diameters of 75.67 and 87.33 nm for drug to carrier ratios of 1:10 and 1:15. See abstract. Thus the instant claims are anticipated by Mohamed et al. Claim Rejections – 35 U.S.C. 103 7. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. 8. Claim(s) 1, 6, 8, 10, and 30-41 is/are rejected under 35 U.S.C. 103 as being unpatentable over Sirianni et al. (U.S. Patent Application Publication No. 2020/0054562) in view of Yang et al. (U.S. Patent Application Publication No. 2018/0326078). Regarding instant claim 1, Sirianni et al. teach a nanoparticle comprising an amphiphilic polymer and a water insoluble biologically active ingredient. See claim 1. The active ingredient comprises a histone deacetylase inhibitor. See claim 41. Regarding instant claims 6 and 30, the polymer is a poly(lactic acid)-polyethylene glycol) (PLA-PEG) polymer or poly(lactic-co-glycolic acid)-poly(ethylene glycol). See claim 33. Regarding instant claim 8, non-limiting examples of the amphiphilic polymer include poly(lactic acid)-poly(ethylene glycol) (PLA-PEG), poly(lactic-co-glycolic acid)-poly(ethylene glycol) (PLGA-PEG), any salts of the foregoing, and any derivatives of the foregoing, etc. See paragraph [0057]. As used herein, the term “derivative” refers to a compound that is synthesized from a parent compound by replacement of one atom with another atom or group of atoms. Non-limiting examples of derivative include a salt, a pharmaceutically acceptable salt, and chemical modifications with a group including but not limited to esters, fluorine, methoxy, ethyl, butyl, propyl, hexyl, or other organic moieties. See paragraph [0039]. Regarding instant claim 10, 5 mg quisinostat was combined with 50 mg PLA-PEG (1:10). See paragraph [0147-0149]. Regarding instant claims 31-34, Sirianni et al. teach use of Poly(d,l-lactide)-b-methoxy poly(ethylene glycol) (PLA-PEG, Mw˜16 k:5 k Da or PLA-PEG, Mw˜20 k:5 k). See paragraph [0144]. Regarding instant claim 35, the weight average molecular weight of PLA is between 5000 and 35000 daltons. See paragraph [0062]. The weight average molecular weight of PEG is between 1000 and 10000 daltons. See paragraph [0063]. The ratio of PLA and PEG (PLA:PEG) is between 50:5 and 10:5, or any number range in between, e.g., about 40:5, about 35:5, about 30:5, about 20:5 or about 16:5. See paragraph [0064]. Regarding instant claim 37, the composition comprises a surfactant. See paragraph [0014]. Examples include poloxamers. See paragraph [0073]. Regarding instant claims 40-41, active ingredients include vorinostat and romidepsin. See paragraph [0018]. Sirianni et al. do not teach Poloxamer 188 and active to surfactant ratio. Yang et al. teach a process for preparing a suspension comprising a microparticle and a pharmaceutically active compound encapsulated in the microparticle and the resulting materials thereof; which process comprises: (a) preparing a solution or suspension (organic phase) comprising: (i) PLGA or PLA or PLA and PLGA, (ii) PLGA-PEG or PLA-PEG and (iii) a pharmaceutically active compound. See paragraphs [0041-0042]. Chemotherapeutic ingredients include vorinostat, romidepsin, etc. See paragraph [0501]. Poly(lactic-co-glycolic acid) (PLGA) polymer, poly(lactic-acid) (PLA) polymer, and diblock co-polymers of PLGA and polyethylene glycol (PLGA-PEG) were purchased from the Evonik Corporation (RESOMER Select 5050 DLG mPEG 5000 (10 wt percent PEG)). See paragraph [1343]. The microparticles include a surfactant such as poloxamer 188. See paragraph [0317]. It would have been obvious to one of ordinary skill in the art as of the effective filing date of the invention to substitute one surfactant for another to yield predictable results. It would have been well within the purview of the skilled artisan to modify the amount and ratio of active to surfactant to enhance mixing of the organic phase and aqueous phase by reducing surface tension. It would have been well within the purview of the skilled artisan to modify the ratio of active to polymer to modify the loading of the active ingredient to achieve the desired effect. Double Patenting 9. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. 10. Claims 1, 6, 8, 10, and 30-41 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-11 of copending Application No. 19/268929 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because both applications are directed to nanoparticles comprising histone deacetylase inhibitors. The instant application further comprises a polymer while Application 19/268929 includes a detectable agent. However, the dependent claims additionally comprise the same type of polymer. Thus, the invention of Application 19/268929 is in effect a "species” of the "generic" invention of the instant application. It has been held that the generic invention is "anticipated" by the "species". See In re Goodman, 29 USPQ2d 2010 (Fed. Cir. 1993). Thus the two are not patentably distinct. The dependent claims are included as being directed to similar additional agents, such as surfactants, and further defining the polymers and amounts. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Conclusion 11. No claims are allowed at this time. 12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JESSICA WORSHAM whose telephone number is (571)270-7434. The examiner can normally be reached Monday-Friday (8-5). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert Wax can be reached at 571-272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JESSICA WORSHAM/Primary Examiner, Art Unit 1615
Read full office action

Prosecution Timeline

Apr 15, 2024
Application Filed
Oct 20, 2026
Non-Final Rejection mailed — §102, §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788019
MAGNESIUM HYDROXIDE FOR USE AS A CONTACT FUNGICIDE IN AGRICULTURE
5y 1m to grant Granted Nov 10, 2026
Patent 12778981
LIPID COMPOSITION CONTAINING MICRONUTRIENTS FOR THE PREVENTION AND/OR TREATMENT OF METABOLIC DISEASES
5y 6m to grant Granted Nov 03, 2026
Patent 12778915
N-PALMITOYL-ETHANOLAMIDE FOR USE IN THE PREVENTION OF COLORECTAL CARCINOMA
4y 7m to grant Granted Nov 03, 2026
Patent 12778896
A METHOD FOR TREATING CANCER WITH AN ORAL DOSAGE FORM OF AN FGFR4 INHIBITOR
3y 11m to grant Granted Nov 03, 2026
Patent 12778956
PROCESS FOR IMPROVING FLUIDITY OF PALBOCICLIB ISETHIONATE AND COMPOSITION
3y 7m to grant Granted Nov 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
56%
Grant Probability
99%
With Interview (+56.4%)
2y 11m (~4m remaining)
Median Time to Grant
Low
PTA Risk
Based on 757 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month